Summary
The folate analogue 5,8-dideazaisopteroylglutamate (IAHQ; NSC-289517) inhibits the growth of a variety of human tumor cells in vitro such as colon, breast and osteosarcoma. Since IAHQ has only modest activity against L1210 leukemia in mice, it was tested in combination with methotrexate (MTX), probenecid, or verapamil in an effort to enhance efficacy. Single drug or drug combinations were administered every other day 3 or 5 times beginning on day 1 following the administration of 106 L1210 cells per animal. The combination of IAHQ (100 mg/kg) plus MTX (10 mg/kg) produced a decrease in mean survival time compared to that of MTX alone, regardless of whether the drugs were initiated on the same day or whether either one was started 2 days prior to the other. IAHQ (150 mg/kg) plus verapamil (5, 10, or 20 mg/kg) did not alter significantly the results produced by IAHQ alone. However, the combination of IAHQ (150 mg/kg) plus probenecid (250 mg/kg) augmented the increase in mean survival time above that produced by IAHQ alone by 82% (p=>0.001). The results suggest that probenecid could be used to enhance the effectiveness of IAHQ against solid tumors such as colon adenocarcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bose AK, Strube RE (1963) Some derivatives of aspartic and glutamic acids. J Pharm Sci 52: 847
Fernandes, DJ, Bertino JR, Hynes JB (1983) Biochemical effects of 5,8-dideazaisopteroylglutamate, a unique quinazoline inhibitor of thymidylate synthase. Cancer Res 43: 1117
Galivan J (1980) Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 17 105
Goldin A, Venditti JM, Mac Donald JS, Muggia JS, Henney JE, DeVita VT (1981) Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 17: 129
Henderson GB, Zevely EM (1985) Inhibitory effects of probenecid on the individual transport routes which mediate the influx and efflux of methotrexate in L1210 cells. Biochem Pharmacol 34: 1725
Hynes JB, Garrett CM (1975) Synthesis of quinazoline analogs of isofolic acid. J Med Chem 18: 632
Hynes JB, Buck JM, D'Souza L, Freisheim JH (1975) Quinazolines as inhibitors of dihydrofolate reductase. 3. Analogs of pteroic and isopteroic acids. J Med Chem 18: 1191
Hynes JB, Yang YCS, McGill JE, Harmon SJ, Washtien WL (1984) Improved synthesis and antitumor evaluation of 5,8-dideazaisofolic acid and closely related analogues. J Med Chem 27: 232
Kessel D, Wilberding C (1985) Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs. Cancer Treat Rep 69: 673
McGuire JJ, Mini E, Hsieh P, Bertino JR (1983) Folylpolyglutamate synthetase relation to methotrexate action and as a target for new drug development. In Chene Y-C, Goz B, Minkoff M (eds) Progress in cancer research and therapy. 28. Development of target-oriented anticancer drugs. Raven, New York, p 97
Rosenblatt DS, Whitehead VM, Vera N, Pottier A, Dupont MM, Vuchich MJ (1978) Prolonged inhibition of DNA synthesis associated with the accumulation of methotrexate polyglutamates by cultured human cells. Mol Pharmacol 14 1143
Rosowsky A, Yu C-S (1983) Methotrexate analogues. 18. Enhancement of the antitumor effect of methotrexate and 3′, 5′-dichloromethotrexate by the use of lipid-soluble diesters. J Med Chem 26: 1448
Ross DA, Gale GR (1979) Reduction of the renal toxicity of cis-dichlorodiammine platinum (II) by probenecid. Cancer Treat Rep 63: 781
Siater LM, Murry SL, Wetzel MW, Sweet P, Stupecky M (1986) Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance. Cancer Chemother Pharmacol 16: 50
Sirotnak FM, Moccio DM, Hancock DH, Young CW (1981) Improved methotrexate therapy of murine tumors obtained by probenecid mediated pharmacological modulation at the level of membrane transport. Cancer Res 41: 3944
Sobrero AF, McGuire JJ, Fernandes DJ, Hynes JB, Bertino JR (1983) Biochemical and antitumor effects of 5,8-dideazai-sopteroylglutamate. In A decade of achievements and challenges in large bowel cancer research 1972–1982. Workshop, Houston, June 23–26, abstracts, p 249
Tsang K-Y, Hynes JB, Fudenberg HH (1982) Effects of 5,8-dideazaisofolic acid (IAHQ) on human tumor cells in culture and on normal and tumor-bearing hamsters. Chemotherapy 28: 276
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1985) Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker. Cancer Treat Rep 69: 523
Tsuruo T, Iida H, Yamashiro M, Tsukagoshi S, Sakurai Y (1982) Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem Pharmacol 31: 3138
Author information
Authors and Affiliations
Additional information
Supported by Public Health Service Grant CA-25014 (National Cancer Institute) from the National Institutes of Health, Department of Health and Human Services, by the Veterans Administration, and by VA-NCI Interagency Agreement IGA V101 (134A) P-77014. Presented in part at the Annual Meeting of the Southeastern Section, Society for Experimental Biology and Medicine, Charleston, SC, November 14–15, 1985.
Rights and permissions
About this article
Cite this article
Hynes, J.B., Smith, A.B. & Gale, G.R. Effects of 5,8-dideazaisopteroylglutamate (IAHQ) on L1210 leukemia in mice when given alone and in combination with methotrexate, probenecid, or verapamil. Cancer Chemother. Pharmacol. 18, 231–234 (1986). https://doi.org/10.1007/BF00273392
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00273392